Downloaded from models for the understanding of the in vivo potency of antiretroviral agents (Jones et al., 2001) .
Our interest in the pharmacokinetics of protease inhibitors led us to determine levels of ␣ 1 -acid glycoprotein (AAG 1 ), an acute phase protein, in HIV-1-infected subjects on antiretroviral drug regimens. Holladay and coworkers (Holladay et al., 2001 ) recently conducted a study in animal models to investigate the disposition of saquinavir, a highly bound protease inhibitor during normal and elevated AAG conditions. The study showed that in the presence of elevated AAG concentrations, such as can occur in patients with advanced HIV disease and low CD4 cell count (Oie et al., 1993; Merry et al., 1996) , the extent of saquinavir binding may increase, influencing drugsystemic exposure, systemic clearance, and volume of distribution.
HIV protease inhibitors are large lipophilic weak basic molecules that strongly bind to AAG (Bilello and Drusano, 1996) . AAG plasma concentrations increase severalfold in response to systemic tissue injury, inflammation, or infection (Fournier et al., 2000) . Binding of basic drugs therefore may be altered during infection resulting in a change in the free fraction and an overall increase in total plasma drug concentration (due to the decrease in apparent volume of distribution) (Fournier et al., 2000) . For this reason, therapeutic drug monitoring of total drug concentrations in patients with elevated AAG levels may be difficult to interpret since there may or may not be a change in free concentration (depending on the clearance, high or low, of drug in question). Moreover, the large variations observed in the binding ratios (unbound/total) of basic drugs in plasma during pathological states are correlated with the large variation in the plasma levels of AAG (Israili and Dayton, 2001) .
Therefore, we measured AAG plasma concentrations in 81 HIVinfected subjects (median age 34 years; range, 21-48; 17 females, 64 males) to investigate the behavior of AAG plasma concentrations in subjects with a chronic viral infection (n ϭ 52 with and n ϭ 29 without active HIV replication detected in plasma) on antiretroviral therapy, not showing any acute comorbidity. Median (range) HIV infection length was 8.7 (1.2-17.1) years. All subjects had been treated with triple antiretroviral regimens for a median (range) period of 45 months (5-78). Median CD4 cell count was 313 (range, 12-931) ϫ 10 6 cell/l. Median log viral load among all patients was 2.3 (range, 1.3-5.5) (Roche Amplicor UltraSensitive assay; Roche Molecular Systems, Somerville, NJ). Plasma AAG levels are considered in the normal range when between 50 to 120 mg ⅐ dl Ϫ1 (Behring Nephelometer Analyzer; Behring Diagnostics, Inc., Somerville, NJ). Median (range) total protein level and median (range) AAG concentration were 8.1 (7.1-9.8) g ⅐ dl Ϫ1 and 79 (15-170) mg ⅐ dl Ϫ1 , respectively.
No significant correlation was observed in our cohort between AAG plasma concentrations and gender, CD4 cell count, plasma HIV-RNA, HIV infection length, and duration of therapy (Table 1) . The normal range of AAG concentrations is wide, and therefore the free fractions of highly bound protease inhibitors may vary considerably with potential implications for pharmacokinetics and drug efficacy over time. The figure shows a normal distribution (in the 81 subjects) in the AAG concentration range. Only a few subjects had decreased (Յ50 mg ⅐ dl Ϫ1 ; n ϭ 9) or increased (Ͼ120 mg ⅐ dl Ϫ1 ; n ϭ 3) AAG levels, and there was no relationship between these values and viral replication ( p ϭ 0.603; Pearson correlation). However, it is possible that AAG distribution, even if in the normal range, may influence the disposition of highly bound drugs and impact antiretroviral drug response.
The wide variation (coefficient of variation 32%) in AAG levels in human plasma (see Fig. 1 ) may be partly due to the fact that AAG has been shown to be a mixture of two or three genetic variants encoded by at least two different genes (Herve et al., 1998) . Moreover, drugs have different binding specificities for different AAG sites (Herve et al., 1993) , and the wide interindividual variability in binding shown for indinavir (Anderson et al., 2000) may partly be explained by this. The sites where protease inhibitors bind are still unknown.
Elevated plasma AAG concentrations have been shown to limit the intracellular accumulation of protease inhibitors in vitro, especially those such as saquinavir and ritonavir, which are highly protein bound (Ͼ95%) (Herve et al., 1998) suggesting that protein binding may play a role in decreasing antiviral activity.
The free fraction of drug in plasma more accurately reflects the drug available to the target cell, and knowing this may help to establish the actual in vivo concentration necessary to achieve an antiviral effect and help to elaborate important pharmacodynamic 
